Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Taxane benefit in breast cancer--a role for grade and chromosomal stability.
A'Hern RP, Jamal-Hanjani M, Szász AM, Johnston SR, Reis-Filho JS, Roylance R, Swanton C. A'Hern RP, et al. Among authors: roylance r. Nat Rev Clin Oncol. 2013 Jun;10(6):357-64. doi: 10.1038/nrclinonc.2013.67. Epub 2013 May 7. Nat Rev Clin Oncol. 2013. PMID: 23648828 Review.
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C. Roylance R, et al. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21784954 Free PMC article.
Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.
Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C. Roylance R, et al. Breast Cancer Res Treat. 2014 Nov;148(1):221-9. doi: 10.1007/s10549-014-3153-x. Epub 2014 Oct 7. Breast Cancer Res Treat. 2014. PMID: 25288231
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C. Jamal-Hanjani M, et al. Among authors: roylance r. Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23. Ann Oncol. 2015. PMID: 26003169 Free article. Clinical Trial.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks KC, Lanman RB, Garcia-Murillas I, Bliss JM, Ring A, Turner NC. Kingston B, et al. Among authors: roylance r. Nat Commun. 2021 Apr 23;12(1):2423. doi: 10.1038/s41467-021-22605-2. Nat Commun. 2021. PMID: 33893289 Free PMC article.
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.
Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C. Lee AJ, et al. Among authors: roylance r. J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19. J Pathol. 2012. PMID: 21953249
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H, Sawyer E, Houghton D, Davidson N, Howell S, Choy J, Harper P, Roylance R, Fharat R, Mohammed K, Ring A, Johnston S. Battisti NML, et al. Among authors: roylance r. Breast Cancer Res Treat. 2019 Apr;174(3):731-740. doi: 10.1007/s10549-019-05134-x. Epub 2019 Jan 17. Breast Cancer Res Treat. 2019. PMID: 30656459
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA.
Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks KC, Lanman RB, Garcia-Murillas I, Bliss JM, Ring A, Turner NC. Kingston B, et al. Among authors: roylance r. Nat Commun. 2021 Jul 16;12(1):4479. doi: 10.1038/s41467-021-24791-5. Nat Commun. 2021. PMID: 34272402 Free PMC article. No abstract available.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
95 results